FDA Inspection 1309236 — Samer Nakhle, M.D.
The FDA completed an inspection of Samer Nakhle, M.D. on Feb 6, 2026 in Las Vegas, NV. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- Feb 6, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Las Vegas, NV (United States)
Additional Details
Clinical Investigator (CI)